Related references
Note: Only part of the references are listed.Clinical Management of Migraine
Maria Albanese
JOURNAL OF CLINICAL MEDICINE (2022)
Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance
Simona Sacco et al.
JOURNAL OF HEADACHE AND PAIN (2021)
Medication overuse and drug addiction: a narrative review from addiction perspective
Tatiane Teru Takahashi et al.
JOURNAL OF HEADACHE AND PAIN (2021)
Narrative Medicine to integrate patients', caregivers' and clinicians' migraine experiences: the DRONE multicentre project
Maria Clara Tonini et al.
NEUROLOGICAL SCIENCES (2021)
Wearing Off Effect of OnabotulinumtoxinA Near the End of Treatment Cycle for Chronic Migraine: A 4-Year Clinical Experience
Fawad A. Khan et al.
HEADACHE (2020)
Wear-Off of OnabotulinumtoxinA Effect Over the Treatment Interval in Chronic Migraine: A Retrospective Chart Review With Analysis of Headache Diaries
Ruth Ruscheweyh et al.
HEADACHE (2020)
Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019
T. J. Steiner et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study
Paul K. Winner et al.
DRUG SAFETY (2019)
Understanding the nature of psychiatric comorbidity in migraine: a systematic review focused on interactions and treatment implications
Thomas Dresler et al.
JOURNAL OF HEADACHE AND PAIN (2019)
OnabotulinumtoxinA Wear-off Phenomenon in the Treatment of Chronic Migraine
Alina Masters-Israilov et al.
HEADACHE (2019)
Wearing Off Response to OnabotulinumtoxinA in Chronic Migraine: Analysis in a Series of 193 Patients
Sonia Quintas et al.
PAIN MEDICINE (2019)
OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study
C. Dominguez et al.
EUROPEAN JOURNAL OF NEUROLOGY (2018)
Anxiety and depression symptoms and migraine: a symptom-based approach research
Mario Fernando Prieto Peres et al.
JOURNAL OF HEADACHE AND PAIN (2017)
A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience
Andrea Negro et al.
JOURNAL OF HEADACHE AND PAIN (2016)
Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin A during more than one year
I. Aicua-Rapun et al.
JOURNAL OF HEADACHE AND PAIN (2016)
Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment
Simona Guerzoni et al.
JOURNAL OF HEADACHE AND PAIN (2016)
Long-term treatment of chronic migraine with OnabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting
Katja Kollewe et al.
JOURNAL OF NEURAL TRANSMISSION (2016)
Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine
Andrew M. Blumenfeld et al.
BMC NEUROLOGY (2015)
Episodic and Chronic Migraine Headache: Breaking Down Barriers to Optimal Treatment and Prevention
Richard B. Lipton et al.
HEADACHE (2015)
Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year?
Eva Cernuda-Morollon et al.
CEPHALALGIA (2015)
The International Classification of Headache Disorders, 3rd edition (beta version)
Andre Bes et al.
CEPHALALGIA (2013)
Psychiatric comorbidities of episodic and chronic migraine
Dawn C. Buse et al.
JOURNAL OF NEUROLOGY (2013)
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial
S. K. Aurora et al.
CEPHALALGIA (2010)
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial
H. C. Diener et al.
CEPHALALGIA (2010)
OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program
David W. Dodick et al.
HEADACHE (2010)
Economic Burden of Transformed Migraine: Results From the American Migraine Prevalence and Prevention (AMPP) Study
Julie Munakata et al.
HEADACHE (2009)
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
Erik von Elm et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2008)
Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A
KR Aoki
NEUROTOXICOLOGY (2005)
Share Paper
